6533b831fe1ef96bd1299705

RESEARCH PRODUCT

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

Jaafar BennounaEnriqueta FelipDiego CortinovisArunava ChakravarttyJuergen AltEric Scott SchaeferMarie CholAlessandro MorabitoAlex A. AdjeiFrancesco GrossiPaola AimoneLuis Paz-aresDavid PlanchardJoan MaierJavier De CastroTommaso De PasNatasha B. LeighlChristos ChouaidMichael Thomas

subject

0301 basic medicineBasaltCancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentBuparlisib03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisSquamous non-small cell lung cancerCancer researchmedicinePhosphatidylinositolbusinessPI3K/AKT/mTOR pathway

description

e20522Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation may contribute to primary and secondary resistance to platinum (Pt)-based chemotherapy (CT) in sqNSCLC. The pan-PI3K inhibi...

https://doi.org/10.1200/jco.2016.34.15_suppl.e20522